Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443060 in amyotrophic lateral sclerosis
NL-OMON49740Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNL747 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability and Open-label extension safety and tolerability. Started Dec 2018; status: completed.
02
Drugs
DNL747
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON49740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49740.